NCE-1 Intelligence & Market Opportunity

Zavzpret

Zavegepant

Antimigraine

Nasal Spray

Zavzpret is a fast-acting nasal spray for the acute treatment of migraine in adults. It provides pain relief and functional recovery, with effects starting as early as 30 minutes after use.

Approval Date

09-Mar-23

NCE-1 Date

09-Mar-27

NCE Date

09-Mar-28

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

244

2027

292

2028

322

2029

349

2030

374

2031

394

2032

396

Molecule profile

Details & specifications

Molecule

Zavegepant

Innovator

PFIZER INC

Dosage Form

Nasal Spray

Strength

10 mg base/spray

Therapeutic Category

Antimigraine

Usage

Acute treatment of migraine with or without aura in adults.

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.